Haemonetics Corporation $HAE Shares Purchased by AQR Capital Management LLC

Key Points

• AQR Capital Management LLC increased its stake in Haemonetics Corporation by 591.6%, acquiring an additional 149,325 shares, bringing its total ownership to about 0.35% of the company.
• Haemonetics reported $1.10 earnings per share for the last quarter, exceeding estimates by $0.09, although its revenue was down 4.4% compared to the previous year.
• Haemonetics has a current consensus rating of "Moderate Buy" from analysts, with a target price of $82.50.

AQR Capital Management LLC raised its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 591.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,565 shares of the medical instruments supplier's stock after purchasing an additional 149,325 shares during the period. AQR Capital Management LLC owned about 0.35% of Haemonetics worth $10,931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP raised its holdings in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after acquiring an additional 192 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Haemonetics in the 1st quarter valued at approximately $65,000. KBC Group NV raised its holdings in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares in the last quarter. AlphaQuest LLC lifted its position in shares of Haemonetics by 71.5% during the 1st quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier's stock worth $200,000 after purchasing an additional 1,309 shares during the last quarter. Finally, Vise Technologies Inc. grew its stake in shares of Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock worth $221,000 after purchasing an additional 225 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Performance

NYSE HAE traded down $0.39 on Tuesday, reaching $50.96. The stock had a trading volume of 1,578,034 shares, compared to its average volume of 874,684. The stock has a market cap of $2.46 billion, a P/E ratio of 15.58, a price-to-earnings-growth ratio of 0.95 and a beta of 0.39. Haemonetics Corporation has a 12-month low of $50.53 and a 12-month high of $94.99. The business's 50-day moving average price is $62.79 and its 200 day moving average price is $65.18. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. During the same period last year, the firm posted $1.02 EPS. Haemonetics's revenue for the quarter was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, equities analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Barrington Research cut their price target on Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Baird R W upgraded Haemonetics to a "strong-buy" rating in a research note on Wednesday, June 25th. Citigroup raised Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target for the company in a report on Wednesday, July 9th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $62.00 price target (down from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Finally, Robert W. Baird initiated coverage on shares of Haemonetics in a report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $78.78.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.